Literature DB >> 16604073

Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression.

Jodie L Babitt1, Franklin W Huang, Diedra M Wrighting, Yin Xia, Yisrael Sidis, Tarek A Samad, Jason A Campagna, Raymond T Chung, Alan L Schneyer, Clifford J Woolf, Nancy C Andrews, Herbert Y Lin.   

Abstract

Hepcidin is a key regulator of systemic iron homeostasis. Hepcidin deficiency induces iron overload, whereas hepcidin excess induces anemia. Mutations in the gene encoding hemojuvelin (HFE2, also known as HJV) cause severe iron overload and correlate with low hepcidin levels, suggesting that hemojuvelin positively regulates hepcidin expression. Hemojuvelin is a member of the repulsive guidance molecule (RGM) family, which also includes the bone morphogenetic protein (BMP) coreceptors RGMA and DRAGON (RGMB). Here, we report that hemojuvelin is a BMP coreceptor and that hemojuvelin mutants associated with hemochromatosis have impaired BMP signaling ability. Furthermore, BMP upregulates hepatocyte hepcidin expression, a process enhanced by hemojuvelin and blunted in Hfe2-/- hepatocytes. Our data suggest a mechanism by which HFE2 mutations cause hemochromatosis: hemojuvelin dysfunction decreases BMP signaling, thereby lowering hepcidin expression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16604073     DOI: 10.1038/ng1777

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  394 in total

Review 1.  The hepcidin-ferroportin system as a therapeutic target in anemias and iron overload disorders.

Authors:  Tomas Ganz; Elizabeta Nemeth
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

2.  BMPER protein is a negative regulator of hepcidin and is up-regulated in hypotransferrinemic mice.

Authors:  Neeta Patel; Patarabutr Masaratana; Javier Diaz-Castro; Gladys O Latunde-Dada; Aakafa Qureshi; Pamela Lockyer; Molly Jacob; Matthew Arno; Pavle Matak; Ragai R Mitry; Robin D Hughes; Anil Dhawan; Cam Patterson; Robert J Simpson; Andrew T McKie
Journal:  J Biol Chem       Date:  2011-12-05       Impact factor: 5.157

3.  The RGM protein DRAG-1 positively regulates a BMP-like signaling pathway in Caenorhabditis elegans.

Authors:  Chenxi Tian; Debjeet Sen; Herong Shi; Marisa L Foehr; Yevgeniy Plavskin; Olena K Vatamaniuk; Jun Liu
Journal:  Development       Date:  2010-06-09       Impact factor: 6.868

4.  Soluble repulsive guidance molecule c/hemojuvelin is a broad spectrum bone morphogenetic protein (BMP) antagonist and inhibits both BMP2- and BMP6-mediated signaling and gene expression.

Authors:  Mahta Nili; Ujwal Shinde; Peter Rotwein
Journal:  J Biol Chem       Date:  2010-06-08       Impact factor: 5.157

Review 5.  Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation.

Authors:  Chia Chi Sun; Valentina Vaja; Jodie L Babitt; Herbert Y Lin
Journal:  Am J Hematol       Date:  2012-01-31       Impact factor: 10.047

6.  Iron-mediated retinal degeneration in haemojuvelin-knockout mice.

Authors:  Jaya P Gnana-Prakasam; Amany Tawfik; Michelle Romej; Sudha Ananth; Pamela M Martin; Sylvia B Smith; Vadivel Ganapathy
Journal:  Biochem J       Date:  2012-01-15       Impact factor: 3.857

Review 7.  Iron homeostasis and the inflammatory response.

Authors:  Marianne Wessling-Resnick
Journal:  Annu Rev Nutr       Date:  2010-08-21       Impact factor: 11.848

8.  Novel tools for the evaluation of iron metabolism.

Authors:  Léon Kautz; Elizabeta Nemeth
Journal:  Haematologica       Date:  2010-12       Impact factor: 9.941

9.  Interrelationships between tissue iron status and erythropoiesis during postweaning development following neonatal iron deficiency in rats.

Authors:  Narasimha V Hegde; Erica L Unger; Gordon L Jensen; Pamela A Hankey; Robert F Paulson
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-12-30       Impact factor: 4.052

Review 10.  Modulation of hepcidin as therapy for primary and secondary iron overload disorders: preclinical models and approaches.

Authors:  Paul J Schmidt; Mark D Fleming
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.